Improved bioavailability of orally administered mifepristone from PLGA nanoparticles

International Journal of Pharmaceutics

Volumn 334, Issue 1-2, 2007, Pages 173-178

  He, Weiling ^a   Horn, Steven W ^a   Hussain, M Delwar ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

Bioavailability; Mifepristone; Nanoparticles; Oral sustained release; Poly(dl lactide co glycolide) (dl PLGA)

Indexed keywords

MIFEPRISTONE; NANOPARTICLE; POLYGLACTIN; POLYGLACTIN 1A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COYOTE; DRUG BIOAVAILABILITY; DRUG FORMULATION; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

2-PROPANOL; ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRACEPTIVES, ORAL, SYNTHETIC; COYOTES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; LACTIC ACID; MALE; MIFEPRISTONE; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCTION; SOLUBILITY;

EID: 33947148323     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.10.025     Document Type: Article

References (25)

1. Belanoff J.K., Jurik J., Schatzberg L.D., DeBattista C., and Schatzberg A.F. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J. Mol. Neurosci. 19 (2002) 201-206
2. Creinin M.D. Medical abortion regimens: historical context and overview. Am. J. Obstet. Gynecol. 183 (2000) S3-S9
3. Damge C., Aprahamian M., Humbert W., and Pinget M. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol. 52 (2000) 1049-1056
4. DeBattista C., and Belanoff J. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 125-129
5. Eisinger S.H., Meldrum S., Fiscella K., le Roux H.D., and Guzick D.S. Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 101 (2003) 243-250
6. Eldridge J.H., Hammond J., Meulbroek J.A., Staas J.K., Gilley R.M., and Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradables target the Peyer's patches. J. Control. Release 11 (1990) 205-214
7. Fattal E., Pecquet S., Couvreur P., and Andremont A. Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int. J. Pharm. 242 (2002) 15-24
8. Florence A.T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14 (1997) 259-266
9. Fulzele S.V., Satturwar P.M., and Dorle A.K. Study of the biodegradation and in vivo biocompatibility of novel biomaterials. Eur. J. Pharm. Sci. 20 (2003) 53-61
10. Galindo-Rodriguez S.A., Allemann E., Fessi H., and Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22 (2005) 419-464
11. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin. Pharmacokinet. 33 (1997) 7-17
12. Heikinheimo O., Kekkonen R., and Lahteenmaki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 68 (2003) 421-426
13. Jani P., Halbert G.W., Langridge J., and Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42 (1990) 821-826
14. Kekkonen R., Heikinheimo O., Mandelin E., and Lahteenmaki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 54 (1996) 229-234
15. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., and Reiner P.B. Beta-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76 (2001) 1121-1128
16. Lanari C., and Molinolo A.A. Progesterone receptors-animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res. 4 (2002) 240-243
17. Pandey R., Ahmad Z., Sharma S., and Khuller G.K. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int. J. Pharm. 301 (2005) 268-276
18. Pomara N., Doraiswamy P.M., Tun H., and Ferris S. Mifepristone (RU 486) for Alzheimer's disease. Neurology 58 (2002) 1436
19. Sarkar N.N. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur. J. Obstet. Gynecol. Reprod. Biol. 101 (2002) 113-120
20. Satturwar P.M., Fulzele S.V., and Dorle A.K. Biodegradation and in vivo biocompatibility of rosin: a natural film-forming polymer. AAPS Pharm. Sci. Technol. 4 (2003) E55
21. Shakweh M., Besnard M., Nicolas V., and Fattal E. Poly(lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. Pharm. Biopharm. 61 (2005) 1-13
22. Steinauer J., Pritts E.A., Jackson R., and Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet. Gynecol. 103 (2004) 1331-1336
23. Stith C., and Hussain M.D. Determination of mifepristone levels in wild canid serum using liquid chromatography. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 794 (2003) 9-15
24. Stith, C., 2004. Non-lethal reproductive control of predatory coyotes. Ph.D. Dessertation, University of Wyoming.
25. Wang G., Shang H.L., Xie Y., Xiao P., Li X.J., Lin T.C., and Li G.Y. Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells. Chin. Med. J. 118 (2005) 333-336